This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): cinacalcet, AMG073, Mimpara (EU), Regpara (Japan), Parareg, KRN1493
Description: Cinacalcet is a second generation calcimimetic, following on NPS's earlier clinical candidate NPS R-568. Cinacalcet is Amgen’s lead calcimimetic compound. Like calcium itself, calcimimetic compounds interact with calcium-sensitive receptors on the parathyroid glands, changing their sensitivity to blood calcium levels and leading to diminished parathyroid hormone (PTH) secretion. Elevated PTH, in all of its forms, is associated with bone pain, fractures, and increased mortality.
Revenue splits for this drug are BioMedTracker estimates.
NPS, Amgen and Kirin
NPS developed AMG073 and other calcimimetics. Amgen partnered with NPS in 1995 to develop and market agents from this program. Kirin partnered with NPS at the same time to develop and market these agents in Japan, Korea, Taiwan, and China. Amgen holds rights to other world markets.
In July 2012, NPS Pharmaceuticals announced that it amended its license agreement with Amgen for royalties from sales of cinacalcet HCl (Sensipar/Mimpara). Under the revised agreement, NPS will receive a one-time $25 million payment in July 2012 in exchange for its rights to receive royalties under the license agreement that are earned after December 31, 2018.
The amendment also limits the royalty offset of the royalty advance that NPS received from Amgen in August 2011 to $8 million per quarter with royalties in excess of $8 million paid to NPS for the respective quarter, thereby extending the...See full deal structure in Biomedtracker
Partners: Shire Pharmaceuticals Group PLC Kyowa Hakko Kirin Co., Ltd. DRI Capital Inc.
Additional information available to subscribers only: